Commonwealth Equity Services LLC Has $579,000 Position in Altimmune, Inc. (NASDAQ:ALT)

Commonwealth Equity Services LLC raised its holdings in Altimmune, Inc. (NASDAQ:ALT) by 9.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 87,110 shares of the company’s stock after purchasing an additional 7,165 shares during the quarter. Commonwealth Equity Services LLC owned 0.12% of Altimmune worth $579,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. North Star Investment Management Corp. bought a new position in shares of Altimmune in the 1st quarter valued at $31,000. CANADA LIFE ASSURANCE Co acquired a new stake in shares of Altimmune during the 1st quarter worth approximately $44,000. Russell Investments Group Ltd. grew its position in shares of Altimmune by 1,150.9% during the 4th quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company’s stock worth $48,000 after buying an additional 3,959 shares during the period. TFO Wealth Partners LLC acquired a new stake in shares of Altimmune during the 1st quarter worth approximately $51,000. Finally, Horizon Wealth Management LLC acquired a new stake in shares of Altimmune during the 2nd quarter worth approximately $66,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Insiders Place Their Bets

In related news, Director David Drutz sold 16,011 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $6.90, for a total value of $110,475.90. Following the transaction, the director now owns 41,958 shares in the company, valued at $289,510.20. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ALT. B. Riley reissued a “buy” rating and issued a $20.00 price target on shares of Altimmune in a research report on Monday, August 12th. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler reiterated an “overweight” rating and set a $25.00 price target on shares of Altimmune in a report on Friday, June 21st. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research note on Thursday, August 22nd. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Altimmune currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.80.

Altimmune Stock Up 2.9 %

ALT stock opened at $7.79 on Friday. The firm has a market cap of $552.33 million, a PE ratio of -4.89 and a beta of 0.08. The business has a 50 day moving average of $6.71 and a 200-day moving average of $7.46. Altimmune, Inc. has a 12-month low of $2.09 and a 12-month high of $14.84.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The business had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 24,778.97% and a negative return on equity of 53.09%. During the same period in the previous year, the company posted ($0.32) earnings per share. On average, research analysts expect that Altimmune, Inc. will post -0.54 earnings per share for the current year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.